Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Comparison of myocardial perfusion between the users of two antiepileptic medications: valproate vs. carbamazepine

Document Type : Original Article

Authors
Zeinab Peymani 1
Abbas Tafakhori 2
Saeed Farzanehfar 3
Farnoosh Larti 4
Ali Hosseini 3
Mehrshad Abbasi 3
1 Department of Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Neurology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
10.22038/aojnmb.2023.67084.1465
Abstract
Objective(s): The prevalence of coronary artery disease (CAD) is high in patients with epilepsy using antiepileptic drugs (AED). Epilepsy, AED, or the type and duration of AED use , may contribute to higher CAD risk.
In this study, myocardial perfusion imaging (MPI) was compared between patients using carbamazepine and valproate.
Method: Out of 73 patients receiving carbamazepine or valproate monotherapy for more than 2 years, visited at a tertiary referral clinic, 32 patients participated in a 2-day stress and rest phases MPI. For each phase, 15-25 mCi 99mTc-MIBI was injected, at peak exercise or by pharmacologic stimulation for the stress phase. SPECT with cardiac gating was done by a dual-head gamma camera and processed and quantified. Scans with at least one definite reversible hypo-perfusion segment were considered abnormal.
Results: Seventeen patients received carbamazepine monotherapy and 15 valproates. Age and duration of AED use were similar between the groups. Two scans were abnormal (6.3%) both in valproate group (13.3%). Duration of AED use was higher in patients with abnormal scans. In patients receiving monotherapy >2 years, the frequency of abnormal MPI was similar between groups (P-value=0.12).  In patients receiving monotherapy > 5 years, prevalence of abnormal MPI was higher in the valproate group (28.6% vs. 0.0%; P-value=0.042). Considering valproate subgroup, ischemic patients had higher duration of AED use, comparing with the normal patients (17.0±4.2 vs. 6.4±4.8, P-value=0.014).
Conclusion: MPIs were abnormal in patients receiving valproate after 5 years compared to patients receiving carbamazepine. Long-term valproate use may increase the risk of CAD.
Keywords
Valproate
Carbamazepine
Myocardial perfusion scan Epilepsy
Coronary artery disease
Subjects
  1. Jansen K, Lagae L. Cardiac changes in epilepsy. Seizure. 2010; 19:455-460.
  2. LoPinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol. 2010; 12:300-308.
  3. Mehrpour M, Shojaie M, Zamani B, Gharibzadeh S, Abbasi M. Atherogenic consequence of antiepileptic drugs: a study of intima-media thickness. Neurol Sci. 2014; 35:253-257.
  4. Lu B, Elliott JO. Beyond seizures and medications: normal activity limitations, social support, and mental health in epilepsy. Epilepsia. 2012; 53:e25-28.
  5. Chuang YC, Chuang HY, Lin TK, Chang CC, Lu CH, Chang WN, et al. Effects of long‐term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012; 53:120-128.
  6. Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010; 23:164- 169.
  7. Chen NC, Chen CH, Lin TK, Chen SD, Tsai MH, Chang CC, et al. Risk of Micro angiopathy in Patients with epilepsy under long-term antiepileptic Drug Therapy. Front Neurol. 2018; 9:113.
  8. Keenan N, Sadlier LG, Wiltshire E. Vascular function and risk factors in children with epilepsy: associations with sodium valproate and carbamazepine. Epilepsy Res. 2014; 108:1087-1094.
  9. Meysamie A, Salarvand F, Khorasanizadeh M, Ghalehtaki R, Eskian M, Ghodsi S, et al. Cardiovascular risk assessment by FRS and SCORE in Iranian adult population. J Diabetes Metab Disord. 2017; 16:35.
  10. Lai Q, Shen C, Zheng Y, Zhang Y, Guo Y, Ding M. Effects of antiepileptic drugs on the carotid artery intima-media thickness in epileptic patients. J Clin Neurol. 2017; 13: 371-379.
  11. Talaat FM, Kamel T, Rabah AM, Ahmed SM, El-Jaafary SI, Abdelaziz GH Epilepsy and antiepileptic drugs: risk factors for atherosclerosis. Int J Neurosci. 2015; 125: 507-511.
  12. Neligan A, Shorvon SD. Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol. 2010; 67:931-940.
  13. Saleh D, Ismail MA, Ibrahim AM. Non-alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci. 2012; 15:68-77.
  14. Sankhyan N, Gulati S, Hari S, Kabra M, Ramakrishnan L, Kalra V. Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: a cross sectional study. Epilepsy Res. 2013; 107:121-126.
  15. Hamed SA, Hamed EA, Hamdy R, Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007; 74:183-192.
  16. Shakirullah Shakir NA, Nazish H. Carbamazepine Verses Valproic Acid as Monotherapy in Epileptic Patients. J Coll Physicians Surg Pak. 2018; 28:357-360.
  17. Bano S, Zuberi NA, Alam SM. Correlation between Hyper homocysteinemia and Common Carotid Artery Intima media Thickness in Carbamazepine treated Epileptic patients using Ultrasonography. Pak J Med Sci. 2017; 33:1205.
  18. Vyas MV, Davidson BA, Escalaya L, Costella J, Saposnik G, Burneo JG. Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review. Epilepsy Res. 2015; 113: 44-67.
  19. Yamamoto Y, Terada K, Takahashi Y, Imai K, Kagawa Y, Inoue Y. Influence of anti-epileptic drugs on serum lipid levels in adult epilepsy patients. Epilepsy Res. 2016; 127:101-106.
  20. Jallon P, Picard F. Bodyweight gain and anticonvulsants. Drug Saf. 2001; 24:969-978.
  21. Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006; 8:643-648.
  22. Sharma TK, Vardey S, Sitaraman S. Evaluate the Effect of Valproate Monotherapy on the Serum Homocysteine, Folate and Vitamin B12 Levels in Epileptic Children. Clin Lab. 2015; 61:933-940.
  23. Ni G, Qin J, Fang Z, Chen Y, Chen Z, Zhou J, Zhou L. Increased homocysteine levels in valproate-treated patients with epilepsy: a meta-analysis. BMJ open. 2014; 4:e004936.
  24. Gorjipour F, Asadi Y, Osguei NK, Effatkhah M, Samadikuchaksaraei A. Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: a systematic review and meta-analysis. Iran Red Crescent Med J. 2013; 15:249.
  25. Emami-Ardekani A, Esteghamati A, Farzanefar S, Abousaidi M, Abbasi M, Abdollahi S, et al. Folate therapy improves the stress-to-rest mean LV volume ratio in myocardial perfusion imaging in patients with diabetes. Ann Nucl Med. 2015; 29:740-744.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 11, Issue 2
July 2023
Pages 122-127